Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (159,809)	$ (102,408)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1	3
Stock-based compensation	3,003	67
Change in fair value of convertible promissory notes (includes related party amounts of $13,196 and $6,258, respectively)	51,469	20,204
Change in fair value of warrant liabilities - related party	43,575	25,911
Non-cash lease costs	2,251	(4)
Amortization of debt discount	292
Issuance of PIK interest debt	87
Acquired in-process research and development - related party	2,500	37,656
Loss on disposal of property and equipment	42
Changes in operating assets and liabilities:
Prepaid expenses and other current assets (includes related party amounts of $0 and $48, respectively)	(11,071)	(116)
Accounts payable, accrued expenses and other long-term liabilities (includes related party amounts of $(4,652) and $4,803, respectively)	2,819	8,548
Accrued interest (includes related party amounts of $717 and $746, respectively)	2,852	2,844
Net cash used in operating activities	(61,989)	(7,295)
Cash flows from investing activities
Cash paid for purchased in-process research and development	(2,500)	(2,763)
Purchases of property and equipment	(4,014)	(45)
Net cash used in investing activities	(6,514)	(2,808)
Cash flows from financing activities
Proceeds from issuance of common stock		1
Proceeds from issuance of common stock in initial public offering	230,006
Payment of initial public offering costs	(19,702)	(789)
Proceeds from issuance of long-term debt, net of issuance costs	14,665
Proceeds from issuance of convertible promissory notes		135,000
Net cash provided by financing activities	224,969	134,212
Net increase in cash, cash equivalents and restricted cash	156,466	124,109
Cash and, cash equivalents and restricted cash-beginning of period	124,566	457
Cash, cash equivalents and restricted cash-end of period	281,032	124,566
Supplemental disclosure of cash flow information
Cash paid for interest	193
Supplemental disclosure of noncash investing and financing activities
Accrued interest exchanged for convertible promissory notes		47
Operating lease	20,317	180
Issuance of Takeda Warrants in connection with Takeda License		30,534
Issuance of common stock in connection with Takeda License		4,357
Unpaid initial public offering costs		$ 1,409
Unpaid property and equipment purchases	1,573
Conversion of convertible promissory notes and interest into common stock	215,364
Conversion of warrant liability into equity	100,020
Accreted final interest payment fees	252
Settlement of ESPP liability in common stock	$ 173